In immediate-release tablet manufacturing, the (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol tetraacetate presents a process boundary not encountered with the parent dapagliflozin: the four O-acetyl groups undergo pH-dependent hydrolysis, with the rate accelerating above pH 6.5 and granulation temperatures above 45 °C. Aqueous high-shear granulation with purified water as binder solvent is therefore replaced by an ethanol or isopropyl alcohol granulation in a top-drive high-shear granulator equipped with a jacketed bowl and vacuum drying capability. A typical pilot-scale batch uses a 10–25 L bowl, impeller tip speed 3.0–5.5 m/s, chopper speed 1500–3000 rpm, and an end-point torque window of 8–20 N·m; the wet mass is dried at 40–50 °C under 60–100 mbar until residual solvent is below the ICH Q3C option 2 limit, milled through a 0.8 mm conidur screen, and final-blended in a bin blender with croscarmellose sodium at 2–4% w/w and magnesium stearate at 0.5–1.25% w/w. The formulation addition ratio is governed by dose equivalence: a 10 mg dapagliflozin equivalent corresponds to 14.1 mg of the tetraacetate based on molecular weights 408.86 g/mol and 576.90 g/mol, placing the active agent at 7.1–14.1% w/w in a 100–200 mg tablet core. Downstream compression on a rotary tablet press with 8 mm round tooling, pre-compression at 3–5 kN, main compression at 8–15 kN, and dwell time 15–30 ms yields uncoated cores that are then film-coated with an aqueous HPMC-based dispersion at 2–3% weight gain in a perforated pan coater. The compliance framework for this scenario includes ICH Q1A(R2) stress testing for hydrolytic degradation, ICH Q3C residual solvent limits for ethanol or isopropyl alcohol, USP <905> content uniformity acceptance value ≤ 15, and USP <711> dissolution testing with apparatus 2 at 50 rpm. Terminal finished product types are immediate-release tablets and film-coated tablets intended for oral administration.

What Limits Roller Compaction Pressure for Moisture-Sensitive Tetraacetate Blends?

Roller compaction is selected when residual water must remain below 2.0% w/w throughout the granulation sequence because the tetraacetate can undergo hydrolytic deacetylation in the presence of free water, and the resulting parent dapagliflozin has different solid-state and dissolution properties. The unit operation produces ribbons from a pre-blend containing the API at 7–14% w/w, microcrystalline cellulose at 25–45% w/w, lactose monohydrate at 35–60% w/w, crospovidone at 2–5% w/w, and magnesium stearate at 0.5–1.0% w/w. Ribbon density is controlled with a roll pressure of 4–8 kN/cm, roll gap 1.5–3.0 mm, and roll speed 3–8 rpm; if the roller compactor uses cantilevered rolls with hydraulic pressure control, roll gap variation should be maintained within ±0.2 mm to avoid ribbon density gradients. The ribbons are milled through an oscillating granulator with 0.8–1.2 mm screen openings. Process failure on production-scale equipment is most commonly observed when the fraction of granules below 45 µm exceeds 35–40%, because excessive fines increase die-filling variation on rotary tablet presses and lead to capping or lamination at compression forces above 12 kN. The pre-blend should therefore maintain a Hausner ratio below 1.25 and a Carr index below 25 before ribbon formation, with bulk density variance between sampled locations kept below 5% to avoid segregation in the feed hopper. Compliance is governed by USP <905> content uniformity, USP <711> dissolution, Ph.Eur. 2.9.36 powder flow, and ICH Q1A(R2) humidity stress testing; no aqueous granulation endpoint is applied. Terminal finished product types are immediate-release tablets and oval film-coated tablets with debossed identification, including strengths equivalent to 5 mg and 10 mg dapagliflozin.

When low-dose capsule filling is transferred from development to production, the primary defect is segregation of the tetraacetate within the powder blend because the low-dose active must remain uniformly distributed in a fill weight of 200–300 mg in size 3 or 4 capsules. Ordered mixing is therefore performed by first passing the API through a 0.250 mm sieve and blending it with lactose monohydrate carrier particles of median size 100–200 µm in a bin blender at 10–25 rpm for 15–30 min; the API mass fraction is 4.7–7.1% w/w for a 10 mg dapagliflozin equivalent (14.1 mg tetraacetate). To prevent detachment of API from carrier surfaces during transfer, the final blend is discharged directly into a capsule filling machine equipped with dosator or tamping-pin stations rather than pneumatically conveyed over long distances, and relative humidity in the filling suite is maintained below 30% RH. The downstream process includes check weighing at 15–20 min intervals, metal detection, and visual inspection of shell integrity; separation of the two-piece capsule body and cap is monitored because the API has no compressibility requirement but must not segregate during machine vibration. Compliance requires USP <905> content uniformity with acceptance value ≤ 15, USP <2040> disintegration, USP <711> dissolution, and ICH Q3D elemental impurities for the filled capsule formulation. Terminal finished product types are hard gelatin capsules and hypromellose (HPMC) capsules.

Aseptic Processing of Poorly Water-Soluble Tetraacetate into Lyophilized Injectable Cake

Aseptic processing of this tetraacetate excludes terminal moist-heat sterilization because the acetyl groups undergo hydrolytic degradation during autoclaving; the manufacturing route therefore uses aseptic filtration followed by lyophilization. The tetraacetate is first dissolved in a non-aqueous or mixed solvent system, commonly containing PEG 400 at 20–40% v/v and/or sulfobutylether-β-cyclodextrin at 5–20% w/v, with water for injection adjusted to a pH between 6.0 and 7.0 using a phosphate or citrate buffer. The proposed addition ratio for exploratory injectable dosing is 0.1–0.5% w/v API, equivalent to 1–5 mg/mL, depending on the final reconstituted dose; published data for this specific configuration is limited, and no compendial monograph for this ester exists, so each batch must be justified under ICH Q8 design-of-experiments documentation. The solution is passed through a 0.22 µm PVDF or PES sterilizing-grade filter into Type I glass vials within an isolator or Grade A/B aseptic filling line, then partially stoppered and lyophilized with a shelf temperature ramp from −40 °C to +25 °C over 36–60 h; collapse of the cake is prevented by maintaining chamber pressure below 100 mTorr during primary drying. Compliance for the injectable route is anchored to 21 CFR 211.167 for sterile drug product testing, USP <788> for subvisible particulate matter, USP <790> for visible particulates, USP <85> for bacterial endotoxins, and ICH Q3C for residual PEG and cyclodextrin-related solvents. Terminal finished product types are lyophilized powder for injection and solution for injection prepared extemporaneously; these formats are for R&D and clinical supply only, not for an approved SGLT2 inhibitor indication.

When Fixed-Dose Combination with Metformin Hydrochloride Requires Bilayer Compression

In fixed-dose combination tablets, the tetraacetate is segregated into a separate layer from metformin HCl because metformin hydrochloride absorbs moisture rapidly and creates an acidic microenvironment upon dissolution; this limits hydrolytic contact and enables independent dissolution control. The tetraacetate layer is prepared by roller compaction or non-aqueous granulation with an API mass fraction of 7–14% w/w, while the metformin HCl layer typically comprises 60–80% w/w metformin HCl within a high-density binder matrix; the total bilayer tablet mass ranges from 800 mg to 1200 mg for 5 mg/500 mg and 10 mg/1000 mg combinations. On a production-scale bilayer rotary tablet press, the first layer is lightly compressed at 3–7 kN, the second layer is added, and the final compression is applied at 12–30 kN with a dwell time of 20–45 ms; pre-compression is varied to control layer hardness without causing cross-layer contamination or cap separation. Finished-batch testing must demonstrate layer separation below 0.5% by weight after friability testing, and dissolution is evaluated in separate media using USP <711> apparatus 2 at 50 rpm with pH 6.8 phosphate buffer for the tetraacetate layer and pH 6.8 or 1.2 media for metformin as specified in the product dossier. Compliance standards include ICH Q1A(R2) photostability and humidity stress, ICH Q3D, Ph.Eur. 2.9.40 uniformity of mass, and USP <905> content uniformity. Terminal finished product types are bilayer tablets and film-coated bilayer tablets for oral administration.

Granule Dosage Form via Fluid-Bed Spray Granulation for Oral Administration

Fluid-bed spray granulation applies the compound's ethanol solution onto a mannitol–lactose substrate at a product temperature of 30–40 °C, inlet air temperature of 45–65 °C, and spray rate of 5–15 g/min/kg substrate; atomization air pressure is maintained at 1.0–2.0 bar to generate droplets with D50 between 10 µm and 25 µm. The API addition ratio is kept at 0.5–2.0% w/w in the finished granule because the intended use is a single-dose sachet or reconstitutable oral suspension rather than a compressed tablet; the low loading reduces the risk of localized supersaturation and particle agglomeration during drying. The downstream production process includes sieving through 0.5–1.0 mm screens to remove agglomerates, blending with sodium stearyl fumarate at 0.25–0.75% w/w, and filling into sachets or bottles under relative humidity below 30% RH. This scenario is governed by ICH Q1A(R2) for humidity stress testing, ICH Q3C for ethanol residual solvent, Ph.Eur. 2.9.40 for uniformity of mass of single-dose preparations, and USP <711> dissolution using apparatus 2 with surfactant-containing media if solubility-limited. Terminal finished product types are granules for oral suspension and single-dose granules in sachet form; packaging must include a desiccant canister or foil overwrap to maintain the dry state.